USPTO rejects WARF's stem cell patent claims

Published on May 4, 2010 at 5:35 AM · No Comments

In what two consumer groups today praised as a victory for open scientific inquiry, the U.S. Patent and Trademark Office has rejected a controversial patent on human embryonic stem cells held by the Wisconsin Alumni Research Foundation (WARF).

"This is a major victory for unfettered scientific research that could lead to cures for some of the most debilitating diseases," said John M. Simpson, Consumer Watchdog's Stem Cell Project Director. The nonprofit, nonpartisan Consumer Watchdog had joined with the Public Patent Foundation in challenging the validity of WARF's stem cell patent claims.

The USPTO's Board of Appeals and Interferences agreed with the groups that the creation of human embryonic stem cell lines was obvious in the light of work that had been done in other species. In order to obtain a patent, work must be both new and non-obvious. Word of the the USPTO board's April 28 decision was received over the weekend.

"We've said from the very beginning that WARF's patents on stem cells are undeserved," said Dan Ravicher, PUBPAT Executive Director. "Should WARF continue to try to defend their unjustified patents, we will continue to prove them invalid."

Joining the two consumer groups in the challenge from the beginning was Dr. Jeanne Loring, now director of the Center for Regenerative Medicine at the Scripps Institute. Later in the case Dr. Alan Trounson, then of Australia's Monash University and now president of the California Institute for Regenerative Medicine, Dr. Douglas Melton of Harvard and Dr. Chad Cowan of Harvard filed affidavits supporting the challenge.

"This is great news for medical research. Human embryonic stem cells hold great promise for advancing human health, and no one has the ethical right to own them." said Dr. Loring. "

Read the PTO Board of Appeals decision here:

Consumer Watchdog, formerly The Foundation for Taxpayer and Consumer Rights, and the Public Patent Foundation appealed to the U.S. Patent Office's Board of Appeals and Interferences after a PTO examiner granted the patent after narrowing its claims. The two groups originally requested a re-examination of the patent in July 2006, along with two other seminal stem cell patents held by WARF. Initially all three patents were rejected, but in 2008 a PTO examiner granted them with narrowed claims.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Ελληνικά | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment